Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule

Thursday, October 30, 2008 1 min read

Key Takeaway: Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule

Full Press Release Details

Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule.